Annexon (ANNX) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Annexon (ANNX) has outperformed Wave Life Sciences (WVE) over the past year, gaining 8.3% versus a loss of 59.9%. Over five years, WVE leads with a -27.9% price change compared with -81.6% for ANNX. Annexon is the larger company by market cap ($646.5 million vs $616.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | WVE |
|---|---|---|
| Share price | $3.41 | $3.13 |
| Market cap | $646.46M | $616.76M |
| 1-day change | -5.28% | -1.88% |
| YTD return | -32.07% | -81.59% |
| 1-year return | +8.25% | -59.92% |
| 5-year return | -81.56% | -27.88% |
| EPS (TTM) | $-1.13 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.73M |
| Revenue growth (YoY) | — | -60.55% |
| Net income (latest FY) | $-206.69M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $7.18 | $21.73 |
| 52-week low | $2.54 | $3.04 |
| Distance from 52-week high | -52.51% | -85.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +352.49% | +450.16% |
| Average volume | 2.90M | 3.17M |
| Shares outstanding | 189.58M | 197.05M |
| Employees | 92 | 317 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed WVE by 68.2 percentage points over the past year.
- The two companies sit in different sectors: Annexon in Health Care and Wave Life Sciences in Healthcare.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
ANNX vs WVE FAQ
Which is bigger, Annexon or Wave Life Sciences?
Annexon (ANNX) is larger, with a market capitalization of $646.46M compared with $616.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, ANNX or WVE?
ANNX returned +8.25% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Wave Life Sciences in the same industry?
No. Annexon is in the Health Care sector, while Wave Life Sciences is in Healthcare.